We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics.
- Authors
Lucaroni, Laura; Georgiev, Tony; Prodi, Eleonora; Puglioli, Sara; Pellegrino, Christian; Favalli, Nicholas; Prati, Luca; Manz, Markus G.; Cazzamalli, Samuele; Neri, Dario; Oehler, Sebastian; Bassi, Gabriele
- Abstract
Purpose: Recently, Pluvicto™ ([177Lu]Lu-PSMA-617), a small-molecule prostate-specific membrane antigen (PSMA) radioligand therapeutic, has been approved by the FDA in metastatic castration-resistant prostate cancer. Pluvicto™ and other PSMA-targeting radioligand therapeutics (RLTs) have shown side effects due to accumulation in certain healthy tissues, such as salivary glands and kidney. Until now, the molecular mechanism underlying the undesired accumulation of PSMA-targeting RLTs had not been elucidated. Methods: We compared the sequence of PSMA with the entire human proteome to identify proteins closely related to the target. We have identified glutamate carboxypeptidase III (GCPIII), N-acetylated alpha-linked acidic dipeptidase like 1 (NAALADL-1), and transferrin receptor 1 (TfR1) as extracellular targets with the highest similarity to PSMA. The affinity of compound 1 for PSMA, GCPIII, NAALADL-1, and TfR1 was measured by fluorescence polarization. The expression of the putative anti-target GCPIII was assessed by immunofluorescence on human salivary glands and kidney, using commercially available antibodies. Results: A fluorescent derivative of Pluvicto™ (compound 1) bound tightly to PSMA and to GCPIII in fluorescence polarization experiments, while no interaction was observed with NAALADL-1 and TfR1. Immunofluorescence analysis revealed abundant expression of GCPIII both in healthy human kidney and salivary glands. Conclusion: We conclude that the membranous expression of GCPIII in kidney and salivary gland may be the underlying cause for unwanted accumulation of Pluvicto™ and other Glu-ureido PSMA radio pharmaceuticals in patients.
- Subjects
CASTRATION-resistant prostate cancer; PROSTATE cancer; RADIOLIGAND assay; GLUTAMIC acid; SALIVARY glands
- Publication
European Journal of Nuclear Medicine & Molecular Imaging, 2023, Vol 50, Issue 3, p957
- ISSN
1619-7070
- Publication type
Article
- DOI
10.1007/s00259-022-05982-8